Evidence map›Paper›PMID 40112284›Full record

ArticleBlood2025

Clonal hematopoiesis is clonally unrelated to multiple myeloma and is associated with specific microenvironmental changes.

Marta Lionetti, Margherita Scopetti, Antonio Matera, Akihiro Maeda, Alessio Marella, Francesca Lazzaroni, Giancarlo Castellano, Sonia Fabris, Stefania Pioggia, Silvia Lonati and 16 more

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Marta LionettiDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.ORCID 0000-0002-3342-9095
Margherita ScopettiDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
Antonio MateraDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
Akihiro MaedaHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID 0000-0003-4797-0314
Alessio MarellaDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
Francesca LazzaroniHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID 0000-0001-5767-7846
Giancarlo CastellanoHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Sonia FabrisHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID 0000-0003-1341-0503
Stefania PioggiaHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Silvia LonatiDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.ORCID 0009-0001-3034-9874
Alfredo MarchettiDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
Alessandra CattaneoFlow Cytometry Laboratory, Clinical Pathology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID 0000-0002-4500-6540
Marta TorneseFlow Cytometry Laboratory, Clinical Pathology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Antonino NeriScientific Directorate, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Claudia LeoniDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.ORCID 0009-0004-8346-0826
Loredana PettineHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID 0000-0001-9553-2082
Valentina TrainiDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.ORCID 0009-0008-5875-2623
Ilaria SilvestrisDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
Marzia BarbieriHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Giuseppina FabbianoHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Domenica RonchettiDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.ORCID 0000-0002-4824-3445
Elisa TaianaHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Claudio De MagistrisHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.ORCID 0009-0007-6583-6836
Matteo C Da ViàHematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Francesco PassamontiDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.
Niccolò BolliDepartment of Oncology and Hematology-Oncology, University of Milan, Milan, Italy.ORCID 0000-0002-1018-5139

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractMultiple myeloma (MM) initiation is dictated by genomic events. However, its progression from asymptomatic stages to an aggressive disease that ultimately fails to respond to treatments is also dependent on changes of the tumor microenvironment (TME). Clonal hematopoiesis of indeterminate potential (CHIP) is a prevalent clonal condition of the hematopoietic stem cell whose presence is causally linked to a more inflamed microenvironment. Here, we demonstrate in 106 patients with MM that CHIP is frequently coexisting with MM at diagnosis, associates with a more advanced Revised International Staging System stage and higher age, and has a nonsignificant trend toward lower median hemoglobin. In our cohort, the 2 conditions do not share a clonal origin. Single-cell RNA sequencing in 16 patients with MM highlights significant TME changes when CHIP is present: decreased naive T cells, a proinflammatory TME, decreased antigen-presenting function by dendritic cells, and expression of exhaustion markers in CD8 cells. Inferred interactions between cell types in CHIP-positive TME suggested that especially monocytes, T cells, and clonal plasma cells may have a prominent role in mediating inflammation, immune evasion, and pro-survival signals in favor of MM cells. Altogether, our data reveal that, in the presence of CHIP, the TME of MM at diagnosis is significantly disrupted in line with what is usually found in more advanced disease, with potential translational implications. Our data highlight the relevance of this association and prompt for further studies on the modifier role of CHIP in the MM TME.

Indexed as

Clonal HematopoiesisHematopoietic Stem CellsMultiple MyelomaTumor MicroenvironmentAdultAgedAged, 80 and overFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNeoplasm StagingProspective StudiesSingle-Cell Gene Expression AnalysisTumor Escape

Identifiers

PMID40112284
PMCPMC12824685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.